In a report released today, Liana Moussatos from Wedbush reiterated a Hold rating on Sangamo Biosciences (NASDAQ: SGMO), with a price target of $9. The company’s shares opened today at $16.05.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.3% and a 45.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.
Sangamo Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $28.40.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.50 and a one-year low of $6.55. Currently, Sangamo Biosciences has an average volume of 2.68M.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. Most recently, in February 2018, Saira Ramasastry, a Director at SGMO sold 9,450 shares for a total of $235,022.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sangamo Therapeutics, Inc. researches and develops transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Lanphier O. Edward II on June 22, 1995 and is headquartered in Richmond, CA.
